Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Protagonist Therapeutics (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel peptide-based drugs to address significant unmet medical needs. Their primary focus is on inflammatory and immunomodulatory diseases, as well as rare blood disorders like polycythemia vera. Utilizing a proprietary technology platform, Protagonist engineers targeted oral and injectable peptide therapeutics designed to offer improved efficacy, safety, and patient convenience. Key pipeline candidates include rusfertide (PTG-300) for polycythemia vera and JNJ-2113 (formerly PN-235), an oral IL-23 receptor antagonist being developed in partnership with Johnson & Johnson for psoriasis and potentially other IL-23 mediated diseases.
Serves as the primary hub for research and development, clinical operations, and corporate administration, driving the discovery and advancement of peptide-based therapeutics.
The facility houses state-of-the-art laboratories for peptide synthesis, screening, and analytical chemistry, alongside office space supporting its scientific, clinical, and administrative teams. Specific architectural highlights are not widely publicized.
The work culture at Protagonist Therapeutics emphasizes innovation, scientific rigor, collaboration, and a patient-centric approach. It aims to foster a dynamic and challenging environment conducive to cutting-edge biopharmaceutical research and development.
The Newark headquarters is central to Protagonist's R&D engine, facilitating the discovery, preclinical, and clinical development of its novel peptide drug candidates. Its location in the San Francisco Bay Area provides access to a rich talent pool and a vibrant biotech ecosystem.
Protagonist Therapeutics maintains a global presence primarily through its international clinical trial operations, which span North America, Europe, and the Asia-Pacific region. The company also engages in strategic global collaborations, exemplified by its partnership with Janssen (a Johnson & Johnson company) for the worldwide development and commercialization of JNJ-2113. Its direct research footprint includes its headquarters in California, USA, and an office in Brisbane, Australia.
770 multiflora Drive
Newark
CA
USA
Address: Level 7, 300 Ann Street, Brisbane, QLD 4000, Australia (Note: This is a common business address; specific suite may vary)
This location facilitates access to Australian research talent, clinical trial sites, and may leverage R&D incentives or collaborations within the Asia-Pacific biomedical ecosystem.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Protagonist Therapeutics' leadership includes:
Protagonist Therapeutics has been backed by several prominent investors over the years, including:
In the past year, Protagonist Therapeutics has strategically enhanced its leadership team with key appointments in scientific and technical operations, aligning with its pipeline advancement and growth. Notable changes include a new Chief Scientific Officer and a new Chief Technical Operations Officer.
Discover the tools Protagonist Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Protagonist Therapeutics likely uses standard corporate email address formats. While not officially published, a common pattern for companies of this nature is [first_initial][last_name]@[companydomain.com]. Other potential formats could include [first_name].[last_name]@[companydomain.com].
[first_initial][last]@protagonist-inc.com
Format
jdoe@protagonist-inc.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Protagonist Therapeutics announced its financial results for the first quarter of 2024, highlighting progress in its clinical programs, including updates on rusfertide for polycythemia vera and JNJ-2113 (in partnership with J&J) for psoriasis. The company also reported its cash position and outlined upcoming milestones....more
Protagonist Therapeutics Press Release • March 4, 2024
Protagonist Therapeutics announced that the comprehensive results from its Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera were published in The New England Journal of Medicine, underscoring the drug's potential efficacy and safety....more
GlobeNewswire • February 27, 2024
The company reported its financial results for the fourth quarter and full year 2023, detailing significant advancements in its pipeline, particularly for rusfertide and the JNJ-2113 program. Key achievements from the year and anticipated catalysts were also discussed....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Protagonist Therapeutics, are just a search away.